JUN 17, 2020 6:30 PM PDT

New test for high-grade serous ovarian cancer

Research published in Clinical Cancer Research describes a new test that is more effective at diagnosing ovarian cancer. The study was carried out by researchers at the University of British Columbia (UBC) in collaboration with colleagues from the University of New South Wales, Huntsman Cancer Institute, Peter MacCallum Cancer Centre, and Mayo Clinic. With data from over 3,800 ovarian cancer patients, the study is one of the largest ovarian cancer investigations conducted. Clinical Cancer Research is a journal of the American Association for Cancer Research. 

"With this new test, we'll be able to give researchers, clinicians and patients more insight into the disease, which could pave the way for more targeted treatment down the road," says senior author Dr. Michael Anglesio, who is an assistant professor in UBC's department of obstetrics and gynecology. 

The researchers are calling the test PrOTYPE, which stands for Predictor of high-grade serous Ovarian carcinoma molecular subTYPE. High-grade serous ovarian cancer is both the most common and deadly kind of ovarian cancer.

Lead author Dr. Aline Talhouk, also an assistant professor in UBC's department of obstetrics and gynecology, commented: "Right now, high-grade serous ovarian cancer patients are all treated the same, but by knowing what subtype their tumor falls into, we can begin to explore how certain treatments may prove more beneficial for individual patients."

Photo: Pixabay

Conventional methods of gene expression analysis testing for high-grade serous ovarian cancer are simply not realistic in clinical settings, say the researchers. PrOTYPE should address previous tests’ shortcomings while providing 95% accuracy in the identification of tumor subtypes, information that could be used to develop more effective treatments for high-grade serous ovarian cancer. 

"This test has opened up new opportunities and treatment avenues to explore. It will be important to re-evaluate treatment options and test new targets for therapeutics in light of this new ability," says Talhouk.

Sources: Clinical Cancer Research, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JUL 15, 2020
Immunology
Immune Memory to Thwart Recurring Cancer
JUL 15, 2020
Immune Memory to Thwart Recurring Cancer
Preventing cancer from returning in the body is an integral part of any anti-cancer treatment plan. New discoveries from ...
JUL 22, 2020
Cancer
Investigating a New Target Against Esophageal Cancer
JUL 22, 2020
Investigating a New Target Against Esophageal Cancer
Esophageal cancer remains one of the most dangerous cancers in the world. Most therapies center around chemotherapy, rad ...
JUL 28, 2020
Clinical & Molecular DX
Cancer Diagnostics Go Skin Deep
JUL 28, 2020
Cancer Diagnostics Go Skin Deep
The average adult human has between 16 and 22 square feet of skin. This multifaceted organ serves a multitude of functio ...
AUG 05, 2020
Cancer
A New Test to Analyze Cell-Free DNA in Cancer Diagnostics
AUG 05, 2020
A New Test to Analyze Cell-Free DNA in Cancer Diagnostics
Cell-free DNA (cfDNA) are small pieces of genomic DNA that have escaped into the bloodstream either through active relea ...
AUG 21, 2020
Cancer
Firefighters risk greater carcinogenic exposure than previously thought
AUG 21, 2020
Firefighters risk greater carcinogenic exposure than previously thought
New research published in the journal Environment International suggests that firefighters may be more exposed to c ...
SEP 02, 2020
Cancer
New contrast dyes detect cancer using tatoo ink
SEP 02, 2020
New contrast dyes detect cancer using tatoo ink
Researchers have developed new cancer detection agents in the form of contrast dyes from tattoo ink. The results of thes ...
Loading Comments...